Zuardi 1983.

Methods	Allocation: randomised. Blindiness: double. Duration: 4 months.
Participants	Diagnosis: schizophrenia (ICD‐9). History: same drugs for 2 months, stable symptoms 1 month, duration hospitalized 0.3 ‐ 26 yrs. N=22. Age: range 26‐ 63 yrs. Sex: 13 M, 9 F. Setting: in hospital.
Interventions	1. Haloperidol decanoate: dose schedule individualized. N=11. 2. Haloperidol oral: dose schedule individualized. N=11.
Outcomes	Mental state (BPRS).* Leaving the study early. Additional medication. Side effects (Bordeleau Scale).* Unable to use ‐ Global Impression (CGI ‐ no SD).
Notes	* Authors supplied additional BPRS & Bordeleau scale data.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear

Diagnostic tools 
 DSM III ‐ Diagnostic Statistical Manual, version 3. 
 ICD‐9 ‐ International Calssification of Diseases, version 9. 
 RDC ‐ Research Diagnostic Criteria.

Rating scales 
 Global impression 
 CGI ‐ Clinical Global Impression.

Mental state 
 BPRS ‐ Brief Psychiatric Rating Scale. 
 CPRS ‐ Comprehensive Psychopathological Rating Scale.

Side effects 
 AIMS ‐ Abnormal Involuntary Movement Side effects. 
 DOTES ‐ Dosage Record & Treatment Emergent Symptom Scale. 
 EPMS ‐ Extrapyramidal Motor Side‐effects. 
 EPSS ‐ Extrapyramidal Side‐effects Symptoms. 
 MARDRS‐ Montgomery‐Asberg Depression Rating Scale. 
 STESS ‐ Total Score of Side Effects Self Rating. 
 TESF ‐ Treatment Emergent Symptom Form. 
 UKU ‐ Side Effects Rating Scale.